. Author manuscript; available in PMC: 2010 Mar 1.

Published in final edited form as: Best Pract Res Clin Haematol. 2009 Mar;22(1):9–23. doi: 10.1016/j.beha.2008.12.001

Table 3.

Effect of venous thromboembolism (VTE) on survival of patients with different cancer types, stratified by initial Surveillance, Epidemiology and End Results (SEER) cancer stage, and adjusted for age, race and gender.

Hazard ratio for death within 1 year among cases with VTE diagnosed in Year 1 vs no VTE (95% confidence interval), adjusted for age, race and gender
Cancer type	Initial stage
Cancer type	Local	Regional	Metastatic
Prostate	5.6 (3.8–8.5)^§	4.7 (1.9–11.5)^§	2.8 (1.5–5.0)^†
Breast	6.6 (3.7–11.8)^§	2.4 (1.3–4.5)^†	1.8 (1.1–2.9)^*
Lung	3.1 (2.1–4.5)^§	2.9 (2.3–3.5)^§	2.5 (2.3–2.7)^§
Colon/rectum	3.2 (1.8–5.5)^§	2.2 (1.7–3.0)^§	2.0 (1.7–2.4)^§
Melanoma	14.4 (4.6–45.2)^§	N/A	2.8 (1.5–5.3)^†
Non-Hodgkin’s lymphoma	3.2 (1.9–5.3)^§	2.0 (1.3–3.2)^†	2.3 (1.7–3.1)^§
Uterus	7.0 (3.4–14.2)^§	9.1 (4.8–17.2)^§	1.7 (1.0–3.0)^*
Bladder	3.2 (1.7–6.2)^§	3.3 (1.7–6.4)^§	3.3 (1.8–6.2)^§
Pancreas	2.3 (1.2–4.6)^*	3.8 (2.8–5.1)^§	2.3 (1.9–2.7)^§
Stomach	2.4 (1.1–5.1)^*	1.5 (1.0–2.1)^*	1.8 (1.4–2.3)^§
Ovary	11.3 (2.5–51.7)^†	4.8 (1.1–20.4)^*	2.3 (1.7–3.0)^§
Kidney	3.2 (1.2–8.8)^*	1.4 (0.6–3.2)	1.3 (0.9–2.0)

Note: VTE was modelled as a time-dependent covariate.

N/A = Not enough VTE cases to estimate.

P<0.05.

^†

P<0.01.

^§

P<0.001.